Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Emmanuelle Gras und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Ba…. Hauptthemen laut MEDLINE: Alanine, Adenosine Monophosphate, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Instituto de Salud Carlos III, Resolución de la Dirección del Instituto de Salud Carlos III, O.A., M.P.
Abstract (Originalsprache)
Objectives
To describe the management of haematological patients experiencing prolonged SARS-CoV-2 viral shedding, as the optimal management strategy for this condition remains undetermined.
Methods
We conducted a retrospective evaluation of our prospectively followed cohort of haematological patients treated with remdesivir for more than 10 days. Starting January 2023, upon COVID-19 diagnosis, the treatment strategy was based on symptoms and PCR cycle threshold (Ct) as follows: (i) when Ct was 25 or less or if the patient had symptoms, a course of remdesivir for at least 10 days, nirmatrelvir/ritonavir for 5 days (whenever possible) and convalescent plasma was administered; and (ii) when the patient was asymptomatic and had a PCR Ct of more than 25, when possible, a course of 5 days of nirmatrelvir/ritonavir was administered. The patient was considered to have achieved viral clearance and, thus, remdesivir was stopped, in either of these cases: (i) PCR negativity, or (ii) subgenomic RNA negativity.
Results
From January to November 2023, 18 patients benefited from a safe extended remdesivir administration, resulting in detection of SARS-CoV-2 viral clearance in a median time of 3.5 weeks (IQR 2.6–3.9) (min–max 1.6–8.0). No clinical or biological side effects were detected. No patient died or needed further treatment for their COVID-19 episode.
Conclusions
The extended course of remdesivir, combined with other active therapies for COVID-19 infection, was well tolerated. Cure and virus negativity were obtained in all these high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Carrer de Villarroel 170, 08036 Barcelona, Spain.
- Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, F75012 Paris, France.
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), c. Casanova, 143, 08036 Barcelona, Spain.
- Department of Hematology, Division of Medicines, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Department of Pharmacy, Division of Medicines, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Department of Microbiology, Hospital Clinic, Universitat de Barcelona, ISGlobal, Barcelona, Spain.
ORCID-Profile: Emmanuelle Gras, Alex Soriano, Carolina Garcia-Vidal
Förderung
- Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III
- Instituto de Salud Carlos III
- Resolución de la Dirección del Instituto de Salud Carlos III, O.A., M.P
- European Union
Zitieren
APA
Gras, E., Aiello, T. F., Chumbita, M., Gallardo-Pizarro, A., Monzó-Gallo, P., Teijón-Lumbreras, C., Suárez-Lledó, M., Magnano, L., Tuset, M., Marcos, M. Á., Soriano, A., & Garcia-Vidal, C. (2024). Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae237
Vancouver
Gras E, Aiello TF, Chumbita M, Gallardo-Pizarro A, Monzó-Gallo P, Teijón-Lumbreras C, et al. Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae237
BibTeX
@article{Gras2024,
author = {Gras, Emmanuelle and Aiello, Tommaso Francesco and Chumbita, Mariana and Gallardo-Pizarro, Antonio and Monzó-Gallo, Patricia and Teijón-Lumbreras, Christian and Suárez-Lledó, Maria and Magnano, Laura and Tuset, Montse and Marcos, Maria Ángeles and Soriano, Alex and Garcia-Vidal, Carolina},
title = {Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae237}
}
EUVIMED